Canadian Journal of Infectious Diseases and Medical Microbiology

Research Article

Biochemical and Molecular Analysis of Staphylococcus aureus Clinical Isolates from Hospitalized Patients

Table 6

Minimum inhibitory concentration of vancomycin of Staphylococcus aureus clinical isolates.


Vancomycin MIC (μg/mL)	MRSA ()			MSSA ()
Vancomycin MIC (μg/mL)	VSSA Number (%)	VISA Number (%)	VRSA Number (%)	VSSA Number (%)	VISA Number (%)	VRSA Number (%)

0.25	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
0.5	3 (4.28)	0 (0)	0 (0)	18 (60)	0 (0)	0 (0)
1	2 (2.85)	0 (0)	0 (0)	12 (40)	0 (0)	0 (0)
2	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
4	0 (0)	10 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)
8	0 (0)	17 (24.3)	0 (0)	0 (0)	0 (0)	0 (0)
16	0 (0)	0 (0)	36 (51.4)	0 (0)	0 (0)	0 (0)
32	0 (0)	0 (0)	2 (2.9)	0 (0)	0 (0)	0 (0)
Total	5 (7.1)	27 (38.6)	38 (54.3)	30 (100)	0 (0)	0 (0)

Positive number; percentage is presented in parenthesis; VSSA: vancomycin-susceptible Staphylococcus aureus; VISA: vancomycin-intermediate Staphylococcus aureus; VRSA: vancomycin resistant Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus.